Bennouna J, et al. - This study was performed to delineate the characteristics of patients receiving bevacizumab plus first-line metastatic chemotherapy for non-squamous advanced non-small cell lung cancer (aNSCLC), with or without brain metastases, in routine clinical practice. In addition, researchers described treatment efficacy, modalities of use, and safety. In a real-life setting, findings confirmed the safety profile and survival benefits of first-line chemotherapy with bevacizumab in aNSCLC patients with brain metastases.